

Funding sources

Myeloma Patients Europe (MPE) – 2019

MPE Industry ¹ related income ²		
Name of company/ funder	Amount of income	% of overall organisation's income
AMGEN	151.125 €	19,50 %
ASTRA ZENECA	300 €	0,04 %
BRISTOL-MYERS SQUIBB	50.520 €	6,52 %
CELGENE	122.644 €	15,82 %
JANSSEN	122.456 €	15,80 %
KARYOPHARM	5899 €	0,76 %

¹ Industry is defined as commercial manufacturers of healthcare products and services, including distributors and wholesalers, etc.

² This should reflect the overall funding received from industry, including, e.g. projects, conferences, etc.

NOVARTIS	35.000 €	4,52 %
ONCOPEPTIDES	10.000 €	1,29 %
SANOFI	75.860 €	9,79 %
TAKEDA	112.798 €	14,55 %
TESARO BIO	25.000 €	3,23 %
Subtotal:	711.602 €	91,81 %

MPE Non-industry related income – Public Funding

Source of funding ³	Amount of income	% of overall organisation's income
H2020 CARAMBA	21.230 €	2,74 %
H2020 MMPredict	6.736 €	0,87 %
IMI Harmony	11.978 €	1,55 %
Subtotal:	39.944 €	5,15 %

³ E.g. membership fees, donations.

MPE Non-industry related income		
CDDF	350 €	0,05 %
European Haematology Association	584 €	0,08 %
ESMO - European Society for Medical Oncology	14.659 €	1,89 %
EUPATI	1.800 €	0,23 %
EURORDIS	285 €	0,04 %
ISPOR	466 €	0,06 %
The Synergist	219 €	0,03 %
WECAN	219 €	0,03 %
Refund - Non Industry (various)	2.045 €	0,26 %
Refund - Social security contribution	3.420 €	0,44 %
Subtotal:	23.544 €	3,04 %
TOTAL⁴:	775.090 €	100%

⁴ In case the total figures in this table do not match those in the financial statement, please provide justification (attached here or as an email).

Information required to be included on organisation's website	Please include links below:
<ul style="list-style-type: none"> Funding sources: 	http://www.mpeurope.org/about-mpe/sponsors/
<ul style="list-style-type: none"> Overall proportion of industry and non-industry: 	Industry: 91,81 %; Non-Industry: 8,19 %.
<ul style="list-style-type: none"> Percentage of the highest contribution from a single company: 	19,50 % of overall organizations income

Comments/explanatory notes:

When completing the form you may refer to the guidance document here (in particular point 4, pages 8-9):

http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2015/05/WC500187018.pdf